# C-Ray Therapeutics Receives Radiopharmaceutical Manufacturing Authorization under China's MAH Framework

- Link: https://www.thailand-business-news.com/pr-news/c-ray-therapeutics-receives-radiopharmaceutical-manufacturing-authorization-under-chinas-mah-framework
- Published: 2026-06-25T10:33:00+07:00
- Author: PR Newswire

CHENGDU, China, June 25, 2026 /PRNewswire/ — On June 23, 2026, C-Ray Therapeutics(
Chengdu) Co., Ltd. ("C-Ray Therapeutics") completed on-site inspections conducted
by a panel of experts from the Sichuan Provincial Center for Drug Evaluation and
the National Defense Science and Industry Administration. The company has officially
obtained the Radiopharmaceutical Production License.

The certification was granted under China’s updated regulatory framework for outsourced
pharmaceutical manufacturing, following strengthened requirements for quality management
systems, responsibility allocation, and on-site inspection standards.

The approval confirms that C-Ray Therapeutics’ compliance system, on-site execution
capability, and reliable supply performance in radiopharmaceutical contract manufacturing
meet regulatory expectations. It also strengthens the foundation for future regulatory
submissions and the commercialization of partnered programs.

Radiopharmaceutical manufacturing is characterized by short production cycles, stringent
quality requirements, and complex supply chain coordination. These factors place
high demands on the compliance systems and operational capabilities of contract 
development and manufacturing organizations.

Guided by its philosophy of "high quality, high efficiency, and first-time-right
execution," C-Ray Therapeutics has established a modern cGMP-compliant manufacturing
facility operated by an experienced technical and regulatory team. To date, the 
company has delivered more than 100 CRDMO projects, covering the full development
lifecycle from early-stage research to commercial supply.

**About C-Ray Therapeutics**

C-Ray Therapeutics is a global CRDMO providing end-to-end radiopharmaceutical development
services — from target validation and preclinical evaluation to IND-enabling studies,
clinical supply, and commercial-scale cGMP manufacturing. Operating from its 28,000-
square-meter Chengdu facility under China’s Class A Radiation Safety License, C-
Ray supports 30+ radioisotopes and has delivered 100+ projects spanning diagnostic
and therapeutic programs, including 5 programs at IND or IND-enabling stage, 29 
have advanced to investigator-initiated trials (IITs), 7 in clinical supply, and
2 in Phase III clinical trials. For more information, visit [www.c-raytherapeutics.com](https://www.c-raytherapeutics.com/)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [C-Ray Therapeutics Receives Radiopharmaceutical Manufacturing Authorization under China's MAH Framework ](http://www.prnasia.com/story/archive/4991227_CN91227_0?rand=184833)